Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent Graft versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant
dc.contributor.author | Choi, Sung Won | |
dc.contributor.author | Reddy, Pavan | |
dc.date.accessioned | 2013-10-21T23:21:19Z | |
dc.date.available | 2013-10-21T23:21:19Z | |
dc.date.issued | 2013-10-21 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/100248 | |
dc.description | UMCC 2008.095 Protocol | en_US |
dc.description.sponsorship | FUNDING Merck and Co., Inc., Leukemia and Lymphoma Society, National Institutes of Health (R01CA143379, 1K23AI091623, P01CA039542, P30CA047904, R01AI15614), St. Baldrick’s Foundation, and Michigan Institute for Clinical and Health Research UL1TR00043. | en_US |
dc.language.iso | en_US | en_US |
dc.subject | GVHD Vorinostat HDAC Inhibition Allogeneic HSCT Reduced Intensity Conditioning | en_US |
dc.title | Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent Graft versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant | en_US |
dc.type | Other | en_US |
dc.subject.hlbsecondlevel | Pediatrics | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.contributor.affiliationum | Pediatrics and Communicable Diseases | en_US |
dc.contributor.affiliationum | Internal Medicine | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/100248/1/umcc_2008 095_protocol.pdf | |
dc.owningcollname | Pediatrics and Communicable Diseases, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.